| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_876f3bc51f16772dd86911c8f3f27ff7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-1019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-07 |
| filingDate |
2004-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ec690564ee237815eb92e8d168e814c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a13cf5d88f4b22143281c0cb85c30fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2548b7f7d0a607c10250d6daaa7ee8ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7df41995204b3236a570a670e56df8b |
| publicationDate |
2006-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1697401-A1 |
| titleOfInvention |
Tetrapeptide regulating blood glucose level in diabetes mellitus |
| abstract |
The invention refers to the field of medicine and can be applied as a substance capable of regulating glucose level while treating and preventing diabetes mellitus. There is proposed a biologically active new tetrapeptide lysyl-glutamyl-aspartyl-tryptophane of general formula Lys-Glu-Asp-Trp-NH2 capable of regulating the glucose level, and pharmacological substance containing an effective amount of tetrapeptide lysyl-glutamyl-aspartyl-tryptophane of the general formula Lys-Glu-Asp-Trp-NH2. There is proposed the method of prevention and/or treatment of the diabetes mellitus, which consists in administering to a patient of the pharmacological substance, containing as an active peptide agent an effective amount of Lys-Glu-Asp-Trp-NH2 tetrapeptide in doses of 0,1 - 30 µg/kg of the body weight at least once a day for a period necessary for attaining a therapeutic effect. |
| priorityDate |
2003-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |